Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.
Stanford is now accepting new patients for this trial.
- Albert Koong, MD, PhD
- Quynh-Thu Le, MD, FACR, FASTRO
- Daniel Chang
- Elizabeth Kidd
- Maximilian Diehn, MD, PhD
- Anson Lowe, MD
- George A. Fisher Jr.
- Billy W. Loo, Jr., MD, PhD, DABR
- Wendy Hara
- procedure : blood draw
Ages Eligible For Study: